PMID- 12902898
OWN - NLM
STAT- MEDLINE
DCOM- 20040128
LR  - 20151119
IS  - 1537-453X (Electronic)
IS  - 0277-3732 (Linking)
VI  - 26
IP  - 4
DP  - 2003 Aug
TI  - Prognostic value of serum IL-18 and nitric oxide activity in breast cancer 
      patients at operable stage.
PG  - 416-21
AB  - Interleukin-18 (IL-18) is a multifunctional cytokine that was previously termed 
      interferon-gamma-inducing factor. It has been suggested that serum IL-18 level 
      may be used as a prognostic factor in some cancer types. Nitric oxide is a potent 
      biologic molecule involved in the pathogenesis of cancer. In this study, we 
      measured serum IL-18 and nitrate + nitrite levels in 56 patients with 
      nonmetastatic breast cancer and 14 control subjects. Serum IL-18* and nitrate + 
      nitrite** levels were significantly higher in patients with breast cancer when 
      compared to the control subjects (*p < 0.05, **p < 0.001). Serum IL-18 levels 
      were significantly higher in patients whose tumor size was greater than or equal 
      to 5 cm when compared to patients whose tumor size was less than or equal to 2 cm 
      (p < 0.05). Patients who were axillary lymph node negative (ALN) had lower serum 
      IL-18 levels when compared to patients with positive ALN (p < 0.001). Serum IL-18 
      levels were significantly higher in patients with stage IIB or IIIA when compared 
      to patients with stage I or IIA (p < 0.05). There was no significant difference 
      in serum nitrate + nitrite levels in terms of age, tumor stage, estrogen 
      receptor, and menopausal and ALN status (p > 0.05). In conclusion, serum IL-18 
      level may be a useful marker to predict prognosis of patients with breast cancer 
      in complete remission after surgery. Long-term follow-up is required to clarify 
      this hypothesis.
FAU - Gunel, Nazan
AU  - Gunel N
AD  - Department of Medical Oncology, Gazi University Medical School, Ankara, Turkey.
FAU - Coskun, Ugur
AU  - Coskun U
FAU - Sancak, Banu
AU  - Sancak B
FAU - Hasdemir, Oguz
AU  - Hasdemir O
FAU - Sare, Mustafa
AU  - Sare M
FAU - Bayram, Orhan
AU  - Bayram O
FAU - Celenkoglu, Gokhan
AU  - Celenkoglu G
FAU - Ozkan, Secil
AU  - Ozkan S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Clin Oncol
JT  - American journal of clinical oncology
JID - 8207754
RN  - 0 (Biomarkers)
RN  - 0 (Carcinoembryonic Antigen)
RN  - 0 (Interleukin-18)
RN  - 0 (Mucin-1)
RN  - 0 (Nitrates)
RN  - 0 (Nitrites)
RN  - 31C4KY9ESH (Nitric Oxide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Breast Neoplasms/*blood/mortality/pathology/therapy
MH  - Carcinoembryonic Antigen/blood
MH  - Female
MH  - Humans
MH  - Interleukin-18/*blood
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Mucin-1/blood
MH  - Nitrates/blood
MH  - Nitric Oxide/*metabolism
MH  - Nitrites/blood
MH  - Prognosis
EDAT- 2003/08/07 05:00
MHDA- 2004/01/30 05:00
CRDT- 2003/08/07 05:00
PHST- 2003/08/07 05:00 [pubmed]
PHST- 2004/01/30 05:00 [medline]
PHST- 2003/08/07 05:00 [entrez]
AID - 10.1097/01.COC.0000027416.15170.53 [doi]
PST - ppublish
SO  - Am J Clin Oncol. 2003 Aug;26(4):416-21. doi: 10.1097/01.COC.0000027416.15170.53.